Vnitr Lek 2006, 52(10):919-925

Incretins

J. Vrbíková*, K. Vondra
Endokrinologický ústav, Praha, ředitel doc. MUDr. Vojtěch Hainer, CSc.

Insulin secretion is greater after peroral challenge than after intravenous glucose administration due to so-called incretin effect. The major incretins are glucagon-like peptide 1 and glucose-dependent-insulinotropic peptide. Physiology, pathophysiology and therapeutic implications of incretins in diabetes, neurodegenerative disorders and stress-induced hyperglycemia are concerned.

Keywords: incretin; glucagon-like peptid 1; glucose-dependent insulinotropic peptide; incretin analogues; dipeptidyl peptidase 4

Received: June 12, 2006; Published: October 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrbíková J, Vondra K. Incretins. Vnitr Lek. 2006;52(10):919-925.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85. Go to original source... Go to PubMed...
    2. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005; 21: 91-117. Go to original source... Go to PubMed...
    3. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718. Go to original source... Go to PubMed...
    4. Baggio LL, Drucker DJ. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab 2004; 18: 531-554. Go to original source... Go to PubMed...
    5. Beinborn M, Worrall CI, McBride EW et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 2005; 130: 1-6. Go to original source... Go to PubMed...
    6. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 2004; 286: R269-R272. Go to original source... Go to PubMed...
    7. Verdich C, Flint A, Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389. Go to original source...
    8. Perry Ta And Greig Nh. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5: 565-571. Go to original source... Go to PubMed...
    9. Young AA, Gedulin BR, Bhavsar S et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034. Go to original source... Go to PubMed...
    10. Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005; 128: 125-134. Go to original source... Go to PubMed...
    11. Nauck MA, Bartels E, Orskov C et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917. Go to original source...
    12. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723. Go to original source... Go to PubMed...
    13. Meier JJ, Hucking K, Holst JJ et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504. Go to original source... Go to PubMed...
    14. Vilsboll T, Krarup T, Madsbad S et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119. Go to original source... Go to PubMed...
    15. Vilsboll T, Knop FK, Krarup T et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003, 88: 4897-4903. Go to original source... Go to PubMed...
    16. Meier JJ, Nauck MA, Schmidt WE et al. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002; 107: 1-13. Go to original source... Go to PubMed...
    17. Zander M, Madsbad S, Madsen JL et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830. Go to original source... Go to PubMed...
    18. Krarup T, Madsbad S, Moody AJ et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 1983; 56: 1306-1312. Go to original source... Go to PubMed...
    19. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253-260. Go to original source... Go to PubMed...
    20. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7. Go to original source... Go to PubMed...
    21. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885. Go to original source... Go to PubMed...
    22. Purnell JQ, Hokanson JE, Marcovina SM et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. Jama 1998; 280: 140-146. Go to original source... Go to PubMed...
    23. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569. Go to original source... Go to PubMed...
    24. Madsbad S, Schmitz O, Ranstam J et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342. Go to original source... Go to PubMed...
    25. Ahren B, Pacini G, Foley JE et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940. Go to original source... Go to PubMed...
    26. Mari A, Sallas WM, He YLet al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894. Go to original source... Go to PubMed...
    27. Meier JJ, Weyhe D, Michaely M et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32: 848-851. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.